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Background: The objective of screening programs is to discover life threatening diseases in as many patients as
early as possible and to increase the chance of survival. To be able to compare aspects of health care quality,
methods are needed for benchmarking that allow comparisons on various health care levels (regional, national, and
international).
Objectives: Applications and extensions of algorithms can be used to link the information on disease phases with
relative survival rates and to consolidate them in composite measures. The application of the developed SAS-macros will
give results for benchmarking of health care quality. Data examples for breast cancer care are given.
Methods: A reference scale (expected, E) must be defined at a time point at which all benchmark objects (observed, O)
are measured. All indices are defined as O/E, whereby the extended standardized screening-index (eSSI), the
standardized case-mix-index (SCI), the work-up-index (SWI), and the treatment-index (STI) address different health care
aspects. The composite measures called overall-performance evaluation (OPE) and relative overall performance indices
(ROPI) link the individual indices differently for cross-sectional or longitudinal analyses.
Results: Algorithms allow a time point and a time interval associated comparison of the benchmark objects in the
indices eSSI, SCI, SWI, STI, OPE, and ROPI. Comparisons between countries, states and districts are possible. Exemplarily
comparisons between two countries are made. The success of early detection and screening programs as well as clinical
health care quality for breast cancer can be demonstrated while the population’s background mortality is concerned.
Conclusions: If external quality assurance programs and benchmark objects are based on population-based and
corresponding demographic data, information of disease phase and relative survival rates can be combined to indices
which offer approaches for comparative analyses between benchmark objects. Conclusions on screening programs and
health care quality are possible. The macros can be transferred to other diseases if a disease-specific phase scale of
prognostic value (e.g. stage) exists.
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In many diseases early detection and secondary preven-
tion are of central importance [1-3]. Life-threatening
malignant diseases are therefore divided into stages
according to their disease phase. They are recorded
using international nomenclatures (e.g. Union for Inter-
national Cancer Control, American Joint Committee in
Cancer) [4,5]. Thus, screening programs are aimed at
discovering diseases in as many patients and as early as
possible to increase their chance of survival.
First approaches on how the number of patients per
disease phase/stage can be linked to the corresponding
chance of survival are based on Beatty et al. [6,7]. They
developed a series of benchmark-algorithms that address
different aspects of health care. Beatty and colleagues
described a screening index based upon the sum of the
products of the stage number (0–4) and the number of
cases at that stage divided by the total number of cases.
Using the stage number in the calculation was consid-
ered arbitrary and it was replaced by the national 5-year
mortality for that stage termed the case-mix index for
the institution or region. This was then standardized by
comparison to the national case-mix index and termed
the standardized case-mix index (SCI). They also
described a standardized work-up index (SWI) to address
the issue of ‘upstaging’ of cases and a standardized treat-
ment index (STI) to evaluate outcome using institutional
or regional mortality (stage and overall) compared to na-
tional mortalities. The product of the SCI, SWI and STI
defined the composite measure named overall perform-
ance evaluation (OPE). They used these indices and eva-
luations to compare different regions over the same time
interval (cross-sectional analysis perspective) and the
same institution across different time intervals (longitu-
dinal analysis perspective).
However, the screening-index was not standardized,
reflected a negative association with the observation
period, and, thus, was not included in the OPE. In
addition, the OPE had a logical weakness, because the
standardized case-mix index was present in the denom-
inator as well as the numerator and cancelled itself out.
Finally, the approach was based on disease-specific cause
of death statistics which required the modeling of com-
peting risks according to the method of Gooley [8]. This
method focuses on the mortality of one disease only
and, therefore reduces the case numbers. This is of spe-
cial importance for small geographic units that already
have small case numbers as it is. This outcome-indicator
also does not include background-mortality.
Objectives
This contribution intends to overcome the existing short-
comings of the proposed algorithms and to extend the
indices (see methods). Furthermore, the automation ofthe benchmark-algorithms (SAS-macros) will standardize
the screening-index, produce a positive association with
the observation time after appropriate mathematical con-
version, and will adequately assess a composite measure.
Disease-specific fatality rates will be replaced by relative
survival rates as outcome-indicators. The macro results
will be demonstrated by exemplary applications. The
development of the indices and the main working hy-
pothesis is built on the assumption that comprehensive
early detection programs are capable of detecting dis-
eases early, leading to disease stage shifts and facilitates
clinical work-up which is associated with increasing
relative 5-year survival rates. Improvements of health
care quality should be illustrated transparently.
Implementations
Data
In general, population based databases with demographic
information such as registers (e.g. cancer register) may
be used. Clinical registers, cohort studies, or health care
network databases are also suited if a high data quality
and epidemiologic relevance is ensured [9-11]. The appli-
cation example is based on the assumption that data of
the Surveillance Epidemiology and End Results (SEER)
[12] and the Norwegian cancer register [13] fulfill these
requirements.
Variables
The variables for the “best-performer“, that must be used
to compare all others, define the reference object. All
other comparative objects are designated as benchmark
objects and must have identification numbers that can
definitely be distinguished from one another. In addition,
information on the year of first definite diagnosis (inci-
dence year) and the disease phase (e.g. for cancer stage
0-IV) is necessary. The absolute and relative distribution
of persons per disease phase (e.g. per stage) as well as the
corresponding relative survival rates (e.g. 5 years) are
needed. In addition, the total number of ill patients per
time unit (e.g. year) and the relative overall survival are
important. Table 1 serves as an example what specifically
the SAS-Macro BenchRelSurv expects as a variable-set in
the so-called long-format of SAS.
Relative survival as outcome
If actually observed and expected chances of survival
probabilities are related to each other, relative survival
rates are obtained [14]. The former originate from em-
pirical data (e.g. registers). But in contrast, the latter can
be calculated from so-called “prospective probability of
death” from period or cohort life tables stratified accord-
ing to age, gender, calendar year and occasionally also
ethnicity [15,16]. These life tables are available from the
Federal Agency for Statistics or the Human Mortality
Table 1 Configuration of Data and Variable Sets
Group Year Identification Stage Number per Stage Number Total Relative Survival
RefGroup RefYear RefID RefStage RefNpStage RefN RefRelSurv
SEER17 1999-2003 1 0 167 191771 93.6
SEER17 1999-2003 1 1 83081 191771 100.00
SEER17 1999-2003 1 2 72195 191771 90.2
SEER17 1999-2003 1 3 12617 191771 61.3
SEER17 1999-2003 1 4 8449 191771 22.5
SEER17 1999-2003 1 5 15262 191771 77.3
SEER17 1999-2003 1 6 191771 191771 89.1
Legend: (Prefix Ref) Definition for reference object substitutable by prefix 'Bench' indicating benchmark object, (Stage) Stage of disease where 5='not known' and
6='total' overall respectively.
Source: New malignant breast cancer cases from Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat.
Database: Incidence - SEER 17-Nov 2010 Sub (1973–2008 varying).
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censored cases [17,18] or various observation periods
[19-21] are possible. Non-parametric methods to derive
relative survival rates are sufficient in this case and can
be easily estimated using freely accessible software-
solutions (e.g. [22]).
Standardized indices
All indices have the principle of construction in common.
Time and factually-fixed reference objects define the com-
parative scale (here USA, 2003). This, so called reference
object is the best possible expected result (expected, Exp*).
All other benchmark objects (observed, Obs) must be com-
pared to this reference scale. Hence, all indices are defined
as: index = Obs/Exp*. From a cross-sectional analysis per-
spective, the benchmark objects (Obs) belong to the same
time interval as the reference object (Exp*). From a longitu-
dinal analysis perspective, however, the benchmark objects
can originate from different time intervals (Obs_t), while
the reference object is fixed in time. To simplify the matter,
the time index t is omitted in the following.
Extended standardized screening index (eSSI)
The central idea of the eSSI is focused on the relative pro-
portion of ill persons per disease stage (N_i/N) weighted by
the stage number itself. The products are then summed up
for the benchmark object. The sum is then put into relation
with the sum of the reference object which characterizes












Standardized case-Mix index (SCI)
The central idea of the SCI is to multiply the absolute
number of ill persons per disease stage (N_i) with the
relative survival rate (RSR_i). The products are thensummed up and divided by the total number of ill
patients. The index is standardized by comparing bench-
















Standardized work-Up index (SWI)
The central idea of the SWI is to relate the relative survival
rate per stage (RSR_i) of a benchmark object (Obs) with
the RSR_i of the reference object (E*). The resulting pro-
portions are then summarized. Finally, to get an idea of the
average relative survival rate across the stages, the sum is
divided by the number of represented disease stages i. The
same is true for the reference object. This index is defined
as:












Standardized treatment index (STI)
The central idea of the STI is to set the overall relative
survival rate (RSR) of benchmark objects (O) and refer-
ence objects (E*) in relation to each other. However,
since benchmark objects and reference objects can differ
in their stage distribution, the SCI is needed as an indi-
cator of risk adjustment. The index is defined as:
STI ¼ O=E ¼ RSR Obs=RSR ExpÞ  1=SCI obsð
Composite measures
According to Beatty et al. [6,7] SCI, SWI, and STI may
be summarized to an overall performance evaluation
(OPE): OPE= SCI × SWI × STI. As an alternative the
relative overall performance index (ROPI) is suggested.
The ROPI is defined as:
ROPI ¼ 1=eSSI SWI STI:
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The data of new malignant breast cancer patients from the
Surveillance Epidemiology and End Results (SEER17-
Nov2010) [12] and the Norwegian cancer register [13]
were used. The national SEER17-values from 1999–2003
served as reference objects in the cross-sectional analyses.
Thus, these analyses were restricted to the period from
1999–2003 and the seventeen SEER-registers which define
the benchmark objects. In the longitudinal analyses, the
national SEER17-values from the last available year 2003
served as reference object. The national SEER17 data from
1990–2003 as well as the Norwegian data from the inter-
vals 1969–73, 1974–78, 1979–1983, 1984–88, 1989–93,
1994–98, and 1999–03 [13] served as benchmark objects.
The relative 5-year survival rate was calculated according
to the Ederer II-method. The examples are available within
the additional files (Additional file 1: Example1, Additional
file 2: Example2) and can be downloaded from the project-
homepage (http://sourceforge.net/projects/benchrelsurv/).Results
In the cross-sectional and longitudinal application exam-
ples, the reference object was also included as bench-
mark object. This leads to a special case because
benchmark object and reference object are equal. There-
fore, the corresponding indices are of value one in
cross-sectional analysis. In longitudinal analyses, it leads
to index values of one in the chosen reference year (here
2003). This logic allows for all the other benchmark
objects that a health service quality gap – or advance –
is identified by index values smaller or larger than one.
If, for example, eSSI>1 is valid, more patients will be
treated at a later time point in the benchmark object
than in the reference object. If eSSI<1 is valid, more
people will be treated at an earlier time point than in
the reference object. The latter result might be inter-
preted as a more effective early detection and screening
program than in the reference object.
In analogy, for SCI>1, the survival conditions in the
benchmark objects will adapt to the normal population’s
faster than in the reference object. If SCI<1 is measured,
the survival conditions in the benchmark object will
adapt more slowly to the conditions of the population
than in the reference object. The latter result might be
interpreted as a less effective early detection and screen-
ing program than in the reference object.
If SWI>1 is true, then the resumed average survival
rates across the stages will be higher in the benchmark
object than in the reference object. If SWI<1 is true,
then the average survival rates across the stages will be
lower in the benchmark objects than in the reference ob-
ject. The latter result might be interpreted as a less ef-
fective clinical work-up than in the reference object.If STI>1 is true, then the stage adjusted overall sur-
vival rates in the benchmark object will be higher than
in the reference object. If STI<1 is true, then the stage
adjusted overall survival rates in the benchmark object
are lower than in the reference object. The latter result
might be interpreted as a less effective overall treatment
than in the reference object.
If OPE or ROPI>1 is valid, then patients in the bench-
mark object will have earlier treatment with higher rela-
tive survival rates on average than in the reference
object. If OPE or ROPI<1 is true, then patients in the
benchmark object will have later treatment with lower
relative survival rates on average than in the reference
object. Table 2 shows the cross-sectional results. Exam-
ples of longitudinal results for the eSSI and ROPI are
depicted in the Figures 1 and 2. The interpretation fol-
lows the general instructions.
Discussion
The existing, updated and extended standardized indices
form an additional tool for the evaluation of health care
services and quality. Reference objects can be defined
and compared to benchmark objects such as countries,
states, and districts. The indices offer a cross-sectional
and longitudinal perspective on benchmark objects. Es-
pecially the latter offer the opportunity to demonstrate
the relationship between disease stage and chance of
survival during the course of time.
Comparison with other benchmarking-algorithms
The performed cross sectional analysis detects the already
observed high variability between urban-metropolitan
areas and rural regions which have led to controversial
discussions [23,24]. The longitudinal analyses, however,
may show the growing influence of comprehensive
early detection and screening-programs and -methods,
guidelines as well as increasing utilization and partici-
pation rates that may lead to more favorable surrogate
parameters such as absolute or relative stage distribu-
tion. In this respect the approach is very similar to
purely descriptive benchmark projects [2,3,25-28],
which also have to interpret obtained results within
country- and time-specific conditions. From this per-
spective both approaches (presented benchmark,
descriptives) are somewhat complementary because the
latter may provide insights in explicitly measured and
process-related quality indicators which are based on
medical decisions. In exchange, the formulated bench-
mark algorithms reject the use of criteria-based
approaches to estimate theoretically expected cases
[1,5,29] in the indices’ denominator. Therefore, the
here presented algorithms cannot inform about insuffi-
cient respectively inappropriate health care. Further-
more, the proposed approach cannot revise short-term
Table 2 Cross-Sectional Benchmarking of SEER17-Registers (1999–2003)
eSSI SCI SWI STI OPE ROPI
Reference Object (1999–2003)
SEER 17 1.000 1.000 1.000 1.000 1.000 1.000
Benchmark Objects
Iowa 0.951 0.993 1.032 1.023 1.048 1.110
New Mexico 0.973 0.959 1.023 1.037 1.017 1.090
Seattle (Puget Sound) 0.960 1.035 1.033 1.004 1.074 1.080
New Jersey 0.991 0.938 0.997 1.052 0.983 1.059
Utah 0.991 0.987 1.026 1.010 1.022 1.045
San Francisco-Oakland (SF) 1.002 1.036 1.039 0.987 1.062 1.023
San Jose-Monterey (SJM) 0.983 1.049 1.009 0.991 1.049 1.018
Conneticut 0.973 1.020 0.985 1.000 1.005 1.013
California excl. SF/SJM/LA 0.994 1.018 1.006 0.990 1.014 1.002
Alaska Natives 0.981 0.932 0.956 0.980 0.874 0.955
Atlanta 1.024 1.001 0.982 0.982 0.965 0.941
Los Angeles (LA) 1.051 1.018 1.008 0.978 1.003 0.938
Kentucky 0.965 0.927 0.862 1.045 0.834 0.933
Detroit (Metropolitan) 1.029 0.981 0.935 0.995 0.913 0.905
Hawaii 0.975 1.078 0.926 0.948 0.947 0.900
Lousiana 1.074 0.960 0.952 0.975 0.891 0.865
Rural Georgia 0.947 0.884 0.709 1.076 0.674 0.805
Legend: (eSSI) Extended Standardized Screening Index, (SCI) Standardized Case-Mix Index, (SWI) Standardized Work-Up Index, (STI) Standardized Treatment Index,
(OPE) Overall Performance Evaluation, (ROPI) Relative Overall Performance Index.
Source: New malignant breast cancer cases from Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat.
Database: Incidence - SEER 17-Nov 2010 Sub (1973–2008 varying).
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ity [4,30], because the chosen outcome parameters of
relative survival are bound to annually presented life
tables. These may also be calculated for shorter time
intervals. In this case the estimation of country-specific
or regional life tables is recommended [31] forFigure 1 Extended Standardized Screening Index (eSSI) for new
malignant breast cancer cases from SEER-17 (1990–2003),
Norway (1969–2003) and SEER-17 (2003) as a reference object.differentiation purposes. Finally, it should be stressed
that the developed approach extends study methods
that are aimed at comparing country-based relative 5-
year survival rates [32-35], because information of ab-
solute and relative stage distribution is linked to the
corresponding survival rates.Figure 2 Relative Overall Performance Index (ROPI) of new
malignant breast cancer cases from SEER 17 (1990–2003), Norway
(1969–2003) and SEER-17 (2003) as a reference object.
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The conceptualization and epidemiological interpret-
ation or health policy conclusions should be drawn in
the country and time-specific context. Therefore, the in-
terpretation of the data examples remains restricted here
to a.) great variations (cross-sectional) between bench-
mark objects and b.) convergence tendencies between
the US and Norway over the course of time.
One contributing factor for this result is measured by
the eSSI and SCI which are both conceptualized on the
premise that the more effective early detection and
screening programs, the more the distribution of cases
will be skewed toward the earlier stages of disease. This
characteristic reflects common knowledge regarding the
coherence between early detection programs and shifts
of stages [36-38] even if screening methods may be dis-
cussed as somewhat controversial in certain age groups
[39]. Also the conceptualization of the SWI captures this
stage migration effect directly. The SWI is based upon
the premise that the more critical the work-up, the more
upstaging will occur and the better the survival at each
stage. However, unless the stage migration alters the
treatments administered, it will not impact the overall
survival, only the survival at each individual stage. The
STI is based upon the premise that the better the over-
all survival corrected for the case-mix, the more effect-
ive the treatment being administered. The utilization of
each of these indices as a benchmark provides a means
of identifying specific areas of program strength and
weakness. The combination of these indices to create
ROPI provides a benchmark for assessment of overall
program quality.
Conceptional pitfalls
The suggested method allows the comparison of coun-
tries, states, and districts on a longitudinal scale. This
perspective offers a high information grade in inter-
national comparisons. However, this means that an espe-
cially high data quality is necessary that must fulfill the
minimum requirements of representative, accurate,
complete, and comparable data [40,41]. Aside from these
formal requirements, some important statistical details
must be regarded which are related to stage distributions
and survival rates.
The comparison of the stage distribution may be
distorted by the stage migration or the so called
“Will-Rogers-Phenomenon“[42-44]. According to this
phenomenon slow growing, “quiet”, and not appar-
ently discernible disease symptoms such as metastases
are discovered earlier due to increasingly powerful im-
aging procedures (diagnostic imaging). This means
these cases are no longer classified as early disease
stages (0-II), but as later ones (III-IV). Thus, the chance
of survival increases in the early disease stages, becausefewer patients with metastases and unfavorable prog-
noses are included. However, the chance of survival
also increases in the later stages, because patients with
metastases that are not apparent are detected earlier.
Due to this effect also known as stage migration dis-
torted stage-specific chances of survival result. The
overall chance of survival, however, is not affected by
this phenomenon [42].
On the contrary, comparison of SWI and STI facili-
tates a greater understanding of the contribution of this
stage migration effect to the overall outcome. For ex-
ample, if the stage-specific survival information (SWI) is
approximately 1.0 and the overall survival information
(STI) is substantially greater than 1.0, the improved
overall outcome adjusted for the stage mix (SCI) appears
to be primarily a treatment effect. On the other hand, if
the SWI is substantially greater than 1.0 but the STI is
approximately 1.0, there is a stage migration occurring
that does not appear to have a major impact on adminis-
tered treatments.
Alongside, the comparison of survival conditions in
time may also be distorted by the so-called lead-time
bias or zero-time shift [42,45]. Accordingly, screening-
tests and diagnostic procedures can identify a disease
even before the patient develops symptoms. This effect
leads to increasing survival times without actually lead-
ing to prolongation of life, if the health care effectiveness
remains constant.
Strengths
Compared to the original indices according to Beatty
et al. [6,7] an extended screening-index (eSSI) is
included, which is standardized in the same logic as all
the other indices and which is expressed as a reciprocal.
Therefore a positive association between the eSS-Index
and the outcome-indicator is established. The latter has
been redefined by substituting the breast cancer-specific
fatality rates by relative survival rates. This approach has
several advantages:
 Overall more patients can be included in the
analyses because survival of all patients is of
concern; regardless of the cause of death. This leads
to a higher statistical power.
 Other causes of death respective frequently reported
misleading information [46,47] do not have to be
modeled in a competing risk model following
Gooley [8].
 Background mortality of the population can be
considered in the model.
 The calculation of the non-parametrically estimated
relative survival rates does not require distribution
assumptions. They can be estimated with existing
software solutions appropriately.
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standardized by variables such as age, gender,
ethnicity etc. limited only by the parameters
available in life tables.
 Benchmark-algorithms and the outcome-indicator
relative survival may be extended to any other
disease as long as a classification in subsequent
disease phases is possible.
The outcome-indicator relative survival can also be
substituted by probabilities. For example, logistic regres-
sions can be calculated to quantify readmission probabil-
ities after inpatient treatment, if the corresponding
benchmark parameter exists. Correspondingly, disease
phases can be substituted by information on disease se-
verity (e.g. Charlson-score, Elixhauser-index [48,49]) as
long as they have an ordinal order.
Weakness
The proposed eSS-Index serves as a level-parameter
(“intercept”) which defines the general premise of the
benchmark respective reference object. Its weakness is
based on the arbitrary weights provided by the stage
numbers which devaluate the earliest disease identified
(stage 0) and emphasize the “not known” (stage 5, see
Table 1). This arbitrariness might decrease the clinical
value of both, the eSSI and ROPI. However, eSSI informs
about stage distributions without any survival informa-
tion and obtains the logical consistency of ROPI.
The conceptual pitfalls of the Will-Roger phenomenon,
stage migration and lead-time bias have already been
mentioned (see above). The former is explored by com-
paring SWI- and STI, but lead-time bias would distort
that assessment and cannot be distinguished from an ap-
parent increase in the incidence of the disease. In
addition, it is highly recommended from a methodo-
logical point of view to estimate outcome-parameters
using the same method but with different regional life
tables. Therefore, population-based data is a crucial pre-
requisite, i.e. the catchment area of integrated networks
or new organization forms in general should be clearly
defined by their landmarks in order to obtain crucial
demographic information from local or regional statis-
tical authorities. In addition, if possible and if these can-
not be avoided, benchmark objects should have the same
structural breaks in their nomenclature of disease phase
(e.g. AJCC, UICC). For example, the UICC Tumor-
Node-Metastasis version 5 (1997–2001) was valid until
version 6 (2002–2008) and version 7 (since 2009) became
effective. The use of the same nomenclature should be
assured for reference and benchmark objects. But from a
practice point of view, this is difficult to achieve due to
time lags in implementation and documentation. Fur-
thermore a fair benchmark has to be assured whichmeans that a comparison between “equivalent” compari-
son objects should be achieved. Thus, homogenous
benchmark objects in terms of “peer-groups” should be
identified [50]. This is recommended since most health
care systems have evolved historically and, thus, infra-
structure characteristics and innovations can be imple-
mented 1:1 from one country, region or district to
another under certain restrictions only [51,52]. However,
the identification of “peer groups” can either be based on
content-related considerations (e.g. countries with national
health care services), on statistically chosen disease-specific
parameters (e.g. distribution of risk, prognosis, and predict-
ive factors) or both [9,53]. Overall incidence-based factors
must be differentiated from patient-, disease-, and health
care system-centered factors [45] which are responsible for
statistical distortion associated with survival analyses.
Perspectives
Benchmark-algorithms that compare countries, states,
and districts are highly complex and require great atten-
tion to research details [40,54]. To be able to take these
into consideration, high quality data is necessary
[9,53,55]. But high data quality in terms of accuracy and
completeness are hard to achieve. In case of the SEER
register for example, some concerns have been docu-
mented [56] which should be thoroughly considered
when results are interpreted for health care decision
making. This approach is even more recommended in-
stead of the growing number of health care providers
who seek to leave the data gathering process due to cost
reductions and missing benefits [57]. However, it is these
data that form the basis to achieve a higher transparency of
efficiency and health care quality which became a crucial
competition parameter in a growing health care industry.
Therefore it is crucial for the next step in quality assurance
to demonstrate how these data may achieve clues of evi-
dence for further improvements. The algorithms proposed
here may serve as first identifier of infrastructural differ-
ences in screening programs and compare these with alter-
nated consequences for the clinical work-up in countries,
states and districts. However from a methodical point of
view, the development of benchmark algorithms is not
complete. Corresponding tests are missing to generate
p-values for which distribution assumptions are requested.
If and under what circumstances certain distributions are
given, will be the task of future developments. Finally, the
clinical meaning and interpretation of index differences
between reference- and benchmark-objects has to be
explored in future applications.
Conclusions
To measure international, national, and regional health
care quality, the suggested algorithms and freely access-
ible SAS-macros BenchRelSurv and BenchRelSurvPlot
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the clinical work-up and effectiveness in general. An ef-
fectiveness comparison is sought that links the earliest
possible time point of a progressive disease with the time
point of an absorbing result after the onset of the pri-
mary disease considering the background mortality (rela-
tive survival). This is especially relevant for diseases (e.g.
breast cancer) where the etiology and disease causes re-
main unclear. However, this concept can also be trans-
ferred to preventable diseases or avoidable mortalities
which have clearly defined disease courses (e.g. cardio-
vascular disease, diabetes mellitus II) and which are
clearly avoidable by (behavioral) interventions. The soft-
ware allows the identification of performance measure-
ment in relation to comparative regions. It offers a first
step towards an in depth research analysis.
Availability and requirements
Project name: Benchmarking relative survival (Bench-
RelSurv, BenchRelSurvPlot)
Project home page: http://sourceforge.net/projects/
benchrelsurv/ delivers files and examples as well as
Technical Reports in German and English
Operating system(s): Platform dependency of SAS 9.2
or higher
Programming language: SAS 9.2 and higher
Other requirements: None
License: None
Any restrictions to use by non-academics: SAS 9.2 li-
cense or higher
Additional files
Additional file 1: Example1.sas: Cross-sectional benchmark for new
malignant breast cancer cases from SEER-17 (1999–2003) registers
with BenchRelSurv and BenchRelSurvPlot.
Additional file 2: Example2.sas: Longitudinal benchmark for new
malignant breast cancer cases from SEER-17 (1990–2003), Norway
(1969–2003) with BenchRelSurv and BenchRelSurvPlot.
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